Abstract:Viral infection triggers the activation of transcription factor IRF3, and its activity is precisely regulated for robust antiviral immune response and effective pathogen clearance. However, how full activation of IRF3 is achieved has not been well defined. Herein, we identified BLK as a key kinase that positively modulates IRF3-dependent signaling cascades and executes a pre-eminent antiviral effect. BLK deficiency attenuates RNA or DNA virus-induced ISRE activation, interferon production and the cellular antiviral response in human and murine cells, whereas overexpression of BLK has the opposite effects. BLK-deficient mice exhibit lower serum cytokine levels and higher lethality after VSV infection. Moreover, BLK deficiency impairs the secretion of downstream antiviral cytokines and promotes Senecavirus A (SVA) proliferation, thereby supporting SVA-induced oncolysis in an in vivo xenograft tumor model. Mechanistically, viral infection triggers BLK autophosphorylation at tyrosine 309. Subsequently, activated BLK directly binds and phosphorylates IRF3 at tyrosine 107, which further promotes TBK1-induced IRF3 S386 and S396 phosphorylation, facilitating sufficient IRF3 activation and downstream antiviral response. Collectively, our findings suggest that targeting BLK enhances viral clearance via specifically regulating IRF3 phosphorylation by a previously undefined mechanism. Transcription factor IRF3-mediated type I interferon production is essential for antiviral innate immunity. Understanding how full activation of IRF3 is regulated is important to decipher the detailed mechanisms of IRF3-dependent signal transduction. Here, we report that BLK promotes IRF3 activation, leading to elevated antiviral cytokine production against multiple invading viruses both in vivo and in vitro . Upon viral infection, BLK undergoes Y309 autophosphorylation and directly phosphorylates IRF3 at Y107, together with TBK1-induced IRF3 S386 and S396 phosphorylation, to achieve sufficient IRF3 activation and elicit robust downstream antiviral responses. Overall, these data suggest that BLK is a critical effector of IRF3 phosphorylation. This study advances the understanding of the precise regulatory mechanisms of IRF3 activation. Manipulation of these mechanisms may help to develop novel therapeutics for infectious and inflammatory diseases.

SHP-1 Suppresses the Antiviral Innate Immune Response by Targeting TRAF3.

Shp-2 Phosphatase Negatively Regulates The Trif Adaptor Protein-Dependent Type I Interferon And Proinflammatory Cytokine Production

NBR1 Mediates Autophagic Degradation of IRF3 to Negatively Regulate Type I Interferon Production.

Phosphatase SHP-1 Promotes TLR- and RIG-I-activated Production of Type I Interferon by Inhibiting the Kinase IRAK1

Lck/Hck/Fgr-Mediated Tyrosine Phosphorylation Negatively Regulates TBK1 to Restrain Innate Antiviral Responses.

Phosphatase Pp4 Negatively Regulates Type I Ifn Production and Antiviral Innate Immunity by Dephosphorylating and Deactivating Tbk1

Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation.

Prohibitin1 facilitates viral replication by impairing the RIG-I-like receptor signaling pathway

Protein Phosphatase PP1 Negatively Regulates the Toll-like Receptor- and RIG-I-like Receptor-Triggered Production of Type I Interferon by Inhibiting IRF3 Phosphorylation at Serines 396 and 385 in Macrophage.

PPM1B negatively regulates antiviral response via dephosphorylating TBK1.

115: Phosphatase PP4 negatively regulates antiviral innate immune response by dephosphorylating TBK1 in macrophages

PZR suppresses innate immune response to RNA viral infection by inhibiting MAVS activation in interferon signaling mediated by RIG-I and MDA5

Herpes Simplex Virus 1 Ubiquitin-Specific Protease UL36 Inhibits Beta Interferon Production by Deubiquitinating TRAF3.

Negative Regulation of RIG-I by Tim-3 Promotes H1N1 Infection.

Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response

SOCS3 Drives Proteasomal Degradation of TBK1 and Negatively Regulates Antiviral Innate Immunity.

Traf-Interacting Protein (Trip) Negatively Regulates Ifn-Beta Production And Antiviral Response By Promoting Proteasomal Degradation Of Tank-Binding Kinase 1

Protein Phosphatase 1 Abrogates IRF7‐mediated Type I IFN Response in Antiviral Immunity

Inducible TAP1 Negatively Regulates the Antiviral Innate Immune Response by Targeting the TAK1 Complex

The Kinase CK1ɛ Controls the Antiviral Immune Response by Phosphorylating the Signaling Adaptor TRAF3

Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling